MARKET

GNPX

GNPX

Genprex Inc
NASDAQ
0.8211
+0.0061
+0.75%
After Hours: 0.8230 +0.0019 +0.23% 19:58 05/22 EDT
OPEN
0.8150
PREV CLOSE
0.8150
HIGH
0.8599
LOW
0.8150
VOLUME
238.68K
TURNOVER
--
52 WEEK HIGH
55.00
52 WEEK LOW
0.7401
MARKET CAP
8.69M
P/E (TTM)
-0.0516
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GNPX last week (0511-0515)?
Weekly Report · 5d ago
Genprex collaborators present positive preclinical data of GPX-002 in diabetes
TipRanks · 05/14 16:54
Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy
TipRanks · 05/14 12:31
Genprex Showcases Positive Preclinical Data On Its Diabetes Gene Therapy Drug Candidate At 2026 American Society Of Gene And Cell Therapy Annual Meeting
Benzinga · 05/14 12:06
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
PR Newswire · 05/14 12:00
Genprex Q1 EPS $(0.64) Up From $(13.00) YoY
Benzinga · 05/13 21:36
Genprex Q1 net loss widens 13% to $4.46 million year over year
PUBT · 05/13 20:36
Weekly Report: what happened at GNPX last week (0504-0508)?
Weekly Report · 05/11 10:16
More
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.

Webull offers Genprex Inc stock information, including NASDAQ: GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.